<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="96">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017493</url>
  </required_header>
  <id_info>
    <org_study_id>02-032021-SULXAG/NO</org_study_id>
    <nct_id>NCT05017493</nct_id>
  </id_info>
  <brief_title>Treatment of Covid-19 With a Herbal Compound, Xagrotin</brief_title>
  <official_title>Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomad AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Directorate of health of Sulaimani, Iraq -KRG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomad AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, multi-center, randomized study. Adults with confirmed covid-19&#xD;
      disease not more than 10 days before enrollment date were recruited (n=361). Patients in same&#xD;
      condition who had treated with standard of care were randomly assigned to the control group&#xD;
      (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also&#xD;
      investigated impact of different characteristics for instance gender, age, duration of&#xD;
      disease, smoking habits and concomitant diseases on the outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, multi-center, randomized study that has been performed in an&#xD;
      outpatient setting (n=361). Adults with confirmed covid-19 disease not more than 10 days&#xD;
      before enrollment date were recruited. Patients in same condition who had treated with&#xD;
      standard of care were randomly assigned to the control group (n=178). The investigators&#xD;
      analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different&#xD;
      characteristics for instance gender, age, duration of disease, smoking habits and concomitant&#xD;
      diseases on the outcome. Adverse events were registered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">February 8, 2021</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Participants who died by day 30 after the enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Disease From Beginning of Treatment</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days the patient has experienced the symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants who have been hospitalized for Covid-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization When Occurred</measure>
    <time_frame>30 days</time_frame>
    <description>Days the participants were hospitalized</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">661</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the Control arm received the standard of care for Covid19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Xagrotin</intervention_name>
    <description>A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or higher&#xD;
&#xD;
          -  Newly diagnosed (no longer than 10 days)&#xD;
&#xD;
          -  PCR or clinically confirmed Covid-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe pulmonary disease&#xD;
&#xD;
          -  Severe cardiovascular disease&#xD;
&#xD;
          -  Severe hepatic disease&#xD;
&#xD;
          -  Severe renal disease&#xD;
&#xD;
          -  Diabetes mellitus type one&#xD;
&#xD;
          -  Metabolic acidosis&#xD;
&#xD;
          -  Oxygen saturation &lt;70%&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Concomitant treatment with anticoagulation drugs&#xD;
&#xD;
          -  Concomitant treatment with CYP3A4 medicines with narrow therapeutic window&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Directorate of health of Sulaimani, Iraq -KRG</name>
      <address>
        <city>Sulaymaniyah</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <results_first_submitted>September 21, 2021</results_first_submitted>
  <results_first_submitted_qc>November 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2021</results_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 30, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT05017493/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT05017493/SAP_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All adult patients in an outpatient setting who were confirmed as coronavirus patients were eligible to be included in the study.</recruitment_details>
      <pre_assignment_details>Age 18 or higher, Newly diagnosed (no longer than 10 days), PCR or clinically confirmed Covid-19</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.&#xD;
Xagrotin: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Patients in the Control arm received the standard of care for Covid19.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment &amp; Care</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Follow up</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Mortality Check</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Both paitients who received and NOT received Xagrotin</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.&#xD;
Xagrotin: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Patients in the Control arm received the standard of care for Covid19.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="483"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="661"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="397"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="547"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="17.16"/>
                    <measurement group_id="B2" value="44.297" spread="17.16"/>
                    <measurement group_id="B3" value="44.1" spread="17.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="483"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="661"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iraq</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="483"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mortality</title>
        <description>Number of Participants who died by day 30 after the enrollment</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.&#xD;
Xagrotin: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Patients in the Control arm received the standard of care for Covid19.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Number of Participants who died by day 30 after the enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Disease From Beginning of Treatment</title>
        <description>Number of days the patient has experienced the symptoms</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.&#xD;
Xagrotin: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Patients in the Control arm received the standard of care for Covid19.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Disease From Beginning of Treatment</title>
          <description>Number of days the patient has experienced the symptoms</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="5.5"/>
                    <measurement group_id="O2" value="18.1" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalization</title>
        <description>Number of participants who have been hospitalized for Covid-19</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.&#xD;
Xagrotin: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Patients in the Control arm received the standard of care for Covid19.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization</title>
          <description>Number of participants who have been hospitalized for Covid-19</description>
          <units>Participatnts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization When Occurred</title>
        <description>Days the participants were hospitalized</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.&#xD;
Xagrotin: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Patients in the Control arm received the standard of care for Covid19.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization When Occurred</title>
          <description>Days the participants were hospitalized</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="4.94"/>
                    <measurement group_id="O2" value="5.5" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>Patients in the Treatment arm received Xagrotin in combination to the standard of care for Covid19.&#xD;
Xagrotin: A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Patients in the Control arm received the standard of care for Covid19.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Xagrotin</sub_title>
                <description>Xagrotin is a herbal compound, and it contains flavonoids, phenols, etc., which dilate blood vessels. Therefore, the risk of internal bleeding is higher in people who take high-dose vasodilators and high-dose Xagrotin at the same time.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Participants got Diarrhea</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="483"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <description>Participants got flatulence</description>
                <counts group_id="E1" events="113" subjects_affected="113" subjects_at_risk="483"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All PIs discuss or publish the results only according to a prior agreement with the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dara Omer</name_or_title>
      <organization>Hiwa Hospital - KRG</organization>
      <phone>+9647701586707</phone>
      <email>mailto:danaomar1979@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

